FILINGS
| AZN 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2024-02-20 | S-8 | FORM S-8 | View Document |
| 2024-02-20 | IRANNOTICE | IRANNOTICE | View Document |
| 2024-02-20 | 20-F | FORM 20-F | View Document |
| 2024-02-20 | 6-K | FORM 6-K | View Document |
| 2024-02-20 | 6-K | ANNUAL FINANCIAL REPORT | View Document |
| 2024-02-20 | SC TO-T/A | SC TO-T/A | View Document |
| 2024-02-20 | 6-K | FORM 6-K | View Document |
| 2024-02-20 | 6-K | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | View Document |
| 2024-02-20 | 6-K | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | View Document |
| 2024-02-20 | 6-K | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | View Document |
| 2024-02-20 | 6-K | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | View Document |
| 2024-02-15 | SC TO-T/A | SC TO-T/A | View Document |
| 2024-02-12 | SC 13G/A | SC 13G/A | View Document |
| 2024-02-08 | 6-K | FINAL RESULTS | View Document |
| 2024-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-01-24 | SC 13G/A | View Document | |
| 2024-01-19 | SC TO-T/A | SC TO-T/A | View Document |
| 2024-01-19 | 6-K | FORM 6-K | View Document |
| 2024-01-11 | SC TO-T/A | SC TO-T/A | View Document |
| 2024-01-10 | CORRESP | View Document | |
| 2024-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-12-27 | SC TO-T | SC TO-T | View Document |
| 2023-12-27 | 6-K | ASTRAZENECA ACQUIRES GRACELL | View Document |
| 2023-12-26 | 6-K | FORM 6-K | View Document |
| 2023-12-22 | 6-K | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | View Document |
| 2023-12-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-12-12 | SC TO-C | SC TO-C | View Document |
| 2023-12-12 | 6-K | FORM 6-K | View Document |
| 2023-12-12 | 6-K | ASTRAZENECA TO ACQUIRE ICOSAVAX | View Document |
| 2023-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2023-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-12-01 | 6-K | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | View Document |
| 2023-11-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-11-17 | 6-K | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | View Document |
| 2023-11-16 | SC 13D/A | SC 13D/A | View Document |
| 2023-11-14 | 25-NSE | View Document | |
| 2023-11-14 | 6-K | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | View Document |
| 2023-11-13 | 144 | View Document | |
| 2023-11-09 | SC 13D | SC 13D | View Document |
| 2023-11-09 | 6-K | DIRECTOR DECLARATION | View Document |
| 2023-11-09 | 6-K | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | View Document |
| 2023-11-09 | 6-K | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | View Document |
| 2023-11-09 | 6-K | 9M AND Q3 2023 RESULTS | View Document |
| 2023-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-11-01 | 6-K | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | View Document |
| 2023-10-03 | 6-K | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | View Document |
| 2023-10-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-09-25 | 6-K | DATO-DXD IMPROVED PFS IN BREAST CANCER | View Document |
| 2023-09-20 | 6-K | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | View Document |
| 2023-09-15 | 6-K | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | View Document |
| 2023-09-11 | 6-K | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | View Document |
| 2023-09-06 | 6-K | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | View Document |
| 2023-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-08-16 | 25-NSE | View Document | |
| 2023-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-07-28 | 6-K | FORM 6K | View Document |
| 2023-07-28 | 6-K | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER | View Document |
| 2023-07-17 | 6-K | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION | View Document |
| 2023-07-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-07-03 | 6-K | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER | View Document |
| 2023-06-28 | 11-K | ANNUAL REPORT | View Document |
| 2023-06-09 | 6-K | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION | View Document |
| 2023-06-09 | 6-K | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS | View Document |
| 2023-06-02 | 6-K | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS | View Document |
| 2023-06-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2023-06-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-06-01 | 6-K | LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER | View Document |
| 2023-05-26 | 6-K | IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER | View Document |
| 2023-05-25 | 25-NSE | View Document | |
| 2023-05-22 | 6-K | DIRECTORATE CHANGE | View Document |
| 2023-05-17 | 6-K | TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER | View Document |
| 2023-05-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-05-09 | 6-K | FARXIGA EXTENDED IN THE US FOR HEART FAILURE | View Document |
| 2023-05-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-05-02 | 6-K | ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER | View Document |
| 2023-05-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-04-27 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2023-04-27 | 6-K | RESULT OF AGM | View Document |
| 2023-04-27 | 6-K | FORM 6-K | View Document |
| 2023-04-27 | 6-K | BOARD COMMITTEE CHANGES | View Document |
| 2023-04-26 | 6-K | DIRECTOR DECLARATION | View Document |
| 2023-04-11 | 6-K | UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI | View Document |
| 2023-04-05 | 6-K | LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER | View Document |
| 2023-04-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-04-03 | 6-K | ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL | View Document |
| 2023-03-30 | 6-K | ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 | View Document |
| 2023-03-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-03-22 | 6-K | FORM 6-K | View Document |
| 2023-03-22 | 6-K | NOTICE OF AGM | View Document |
| 2023-03-15 | CERT | View Document | |
| 2023-03-13 | 8-A12B | 8-A12B | View Document |
| 2023-03-09 | 6-K | IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER | View Document |
| 2023-03-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-03-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-03-06 | 6-K | ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS | View Document |
| 2023-03-03 | 6-K | FORM 6-K | View Document |
| 2023-03-02 | 424B2 | 424B2 | View Document |
| 2023-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-03-01 | 6-K | ASTRAZENECA PRICES A $2.25BN BOND OFFERING | View Document |
| 2023-03-01 | FWP | FWP | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
